
Provisional Authorisation for COVID-19 Tests

<i>Applicant</i>	Siemens Healthcare Pte Ltd
<i>Name of test</i>	Siemens Atellica® IM SARS-CoV-2 IgG (COV2G)
<i>Intended purpose (As per manufacturer's information for use)</i>	<p><i>The Atellica® IM SARS-CoV-2 IgG (COV2G) assay is for in vitro diagnostic use in the qualitative and semi-quantitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the Atellica® IM Analyzer.</i></p> <p><i>This assay is intended as an aid in the diagnosis of patients with suspected SARS-CoV-2 infection and as an aid in identifying patients with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.</i></p>
<i>Date of Provisional Authorisation</i>	13 July 2020
